RxDoctor Payments Data

John Clements

Podiatrist · Roanoke, VANPI 1629012208

Payments from drug & device makers

What this record shows

The money is spread across several categories — royalties or licence payments (51.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Stryker accounts for 96.2% of it on its own, with 19 other manufacturers making up the rest. Among podiatrist clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$924,665in general payments, 2019–2025

Across 441 payments — averaging $2096.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$890K
  • Globus Medical$9K
  • Medical Device Business Services, Inc.$9K
  • Gramercy Extremity Orthopedics LLC$7K
  • Kerecis Limited$5K
  • Forma Medical$3K
  • plus $2K from 14 others
$182,959in research payments, 2019–2025

Across 47 payments — averaging $3892.74 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biotissue Holdings Inc.$179K
  • Stryker$3K
  • Bristol Myers Squibb$2K
$100,000in ownership & investment interests, 2019–2025

Across 7 payments — averaging $14,286 each. An ownership or investment interest held by the physician or an immediate family member.

  • Gramercy Extremity Orthopedics LLC$100K

What the payments were for

  • Royalty or licence$475,10751%
  • Consulting fees$352,50638%
  • Speaking & faculty fees$38,5304%
  • Travel & lodging$50,7625%
  • Food & beverage$7,7011%
  • Ownership interest$600%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$924,665 in reported general payments places this provider in the 95th percentile of 126 podiatrist providers in Virginia.

See all podiatrist providers in Virginia

Medicare billing

Part B allowed, 2024
$160,896
Medicare patients
607
Services billed
1,751

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Celecoxib14$1,407
Gabapentin61$1,162
Pregabalin34$796
Ciclopirox17$608
Diclofenac Sodium60$595
Doxycycline Hyclate43$355
Clindamycin Hcl38$281
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav35$279
Cephalexin50$272
Fluconazole19$259
Levofloxacin47$234
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen37$223
Mupirocin23$214
Silver Sulfadiazine11$83
Meloxicam28$61

Paid to pharmacies, not to this prescriber.

Other podiatrist in Roanoke

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →